Smart Wearables for Cardiac Monitoring-Real-World Use beyond Atrial Fibrillation
- PMID: 33916371
- PMCID: PMC8038592
- DOI: 10.3390/s21072539
Smart Wearables for Cardiac Monitoring-Real-World Use beyond Atrial Fibrillation
Abstract
The possibilities and implementation of wearable cardiac monitoring beyond atrial fibrillation are increasing continuously. This review focuses on the real-world use and evolution of these devices for other arrhythmias, cardiovascular diseases and some of their risk factors beyond atrial fibrillation. The management of nonatrial fibrillation arrhythmias represents a broad field of wearable technologies in cardiology using Holter, event recorder, electrocardiogram (ECG) patches, wristbands and textiles. Implementation in other patient cohorts, such as ST-elevation myocardial infarction (STEMI), heart failure or sleep apnea, is feasible and expanding. In addition to appropriate accuracy, clinical studies must address the validation of clinical pathways including the appropriate device and clinical decisions resulting from the surrogate assessed.
Keywords: arrhythmia; artificial intelligence; cardiac monitoring; digital health; heart failure; mobile health; remote monitoring; wearables.
Conflict of interest statement
D.D. received speaker honoraria and/or travel grants from Abbott, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Medtronic, Pfizer and Zoll. C.V. received honoraria for lectures and/or consulting from Abbott, Astra Zeneca, Bayer, Biotronik, BMS, Boehringer Ingelheim, Boston Scientific, CVRx, Daichii Sankyo, Medtronic and Zoll. T.J.B. received research grants from Boston Scientific, Altathera and Boehringer Ingelheim. D.G. reports speaker honoraria from Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Medtronic, Biosense Webster and Boston Scientific; proctor honoraria for Abbott; and research grants from Medtronic, Biosense Webster and Boston Scientific. P.A.N. received research funding from the National Institutes of Health (NIH, including the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Aging [NIA]), Agency for Healthcare Research and Quality (AHRQ), Food and Drug Administration (FDA) and the American Heart Association (AHA). P.A.N. and Mayo Clinic are involved in a potential equity/royalty relationship with AliveCor. P.A.N. is a study investigator in an ablation trial sponsored by Medtronic. The other authors declare no conflicts of interest.
Figures
References
-
- Calkins H., Hindricks G., Cappato R., Kim Y.-H., Saad E.B., Aguinaga L., Akar J.G., Badhwar V., Brugada J., Camm J., et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation. Europace. 2018;20:e1–e160. doi: 10.1093/europace/eux274. - DOI - PMC - PubMed
-
- Rothman S.A., Laughlin J.C., Seltzer J., Walia J.S., Baman R.I., Siouffi S.Y., Sangrigoli R.M., Kowey P.R. The Diagnosis of Cardiac Arrhythmias: A Prospective Multi-Center Randomized Study Comparing Mobile Cardiac Outpatient Telemetry Versus Standard Loop Event Monitoring. J. Cardiovasc. Electrophysiol. 2007;18:241–247. doi: 10.1111/j.1540-8167.2006.00729.x. - DOI - PubMed
-
- Olson J.A., Fouts A.M., Padanilam B.J., Prystowsky E.N. Utility of Mobile Cardiac Outpatient Telemetry for the Diagnosis of Palpitations, Presyncope, Syncope, and the Assessment of Therapy Efficacy. J. Cardiovasc. Electrophysiol. 2007;18:473–477. doi: 10.1111/j.1540-8167.2007.00779.x. - DOI - PubMed
-
- Engel J.M., Chakravarthy N., Nosbush G., Merkert M., Fogoros M.D.R., Chavan A. Comparison of arrhythmia prevalence in NUVANT mobile cardiac telemetry system patients in the US and India; Proceedings of the 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society; Chicago, IL, USA. 26–30 August 2014; pp. 2730–2733. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
